Transforming lives through first-in-class therapies for oncology and neurology.

  • Insight
  • Discovery
  • Passion

Cavion is a T-type calcium channel platform company delivering first-in-class therapies for the treatment of oncologic and neurologic diseases. The firm is the leader in harnessing the power of the T-type calcium channel (Cav3) as a target for treating patients who suffer from solid tumors or diseases of the nervous system. At Cavion, we bring together scientific insights, superior chemistry and clinical development expertise to deliver novel therapies that transform patients’ lives.

Learn More

With a pipeline of selective T-type calcium channel blockers from its drug discovery platform and in-licensing, Cavion develops oncology drugs that overcome drug resistance by blocking Cav3 to amplify the effects of conventional and targeted therapies and is repositioning non- addictive, non-opioid drugs to transform the prevention and treatment of pain.

Learn More

The ancient Greek poet Archilochus famously wrote that "The fox knows many things, but the hedgehog knows one big thing." Here at Cavion, we know one big thing: Cav3. We passionately pursue therapies based on the T-type calcium channel in order to bring novel, effective, and well-tolerated treatments to patients.

Learn More

Latest News

More +

Contact Us

Cavion